Abstract




Chronic rhinosinusitis (CRS) is a debated topic in the international rhinologic literature because of its high prevalence, heterogeneity of clinical manifestations and unpredictability of disease course. Recently, the focus in CRS research has moved to identify biological sub- types that might explain its aetiology and clinical variability. However, these analyses are still expensive and limited to scientific purposes, so that they cannot be used on a large scale in daily practice. For this reason, we wondered if it was possible to define a risk stratification for CRS patients based only on first level investigations. The heterogeneity of the disease has given us a large amount of data compelling to find an additional storage system. Herein, we present the results of our work, the RhinoBank, as we believe that it is an easy-to-use tool for those professionals dealing with CRS and an effective system to exploit in clinical research.




Article

Chronic rhinosinusitis (CRS) is a frequent disease. Its true prevalence is challenging to be accurately estimated because it depends on the epidemiological methodology employed. However, according to studies based on large-scale questionnaires, it ranges from around 10 to 12% in Europe and the US. Moreover, CRS represents a burden both to individuals and society 1.

In recent years, with the demand to justify therapeutic failures, the scientific community has began to critically review the diagnostic criteria for CRS and realised that they were not sufficient to explain the heterogeneity of the disease. There is, in fact, a broad spectrum of rhinosinusitis manifestations, ranging from simple paranasal sinus dysventilation to frank nasal polyposis, which is not adequately taken into account by the phenotypic classification based on guidelines. The classic dichotomy between CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP) is too simplistic to explain a disorder that is actually considered as a complex multifactorial disease grounded on the interplay between gene-susceptibility and the exposome (microbiota, immunity, epigenetics, nutrition) 2-4.

In the attempt to overcome this limit, we gradually shifted to a different perspective for which the clinical phenotype is in reality nothing but the emerging part of a massive iceberg.

All these considerations were inherited from the pulmonology field. Studies on asthma endotyping have been mentioned since 2008, when the literature began to put a new focus on pathogenetic mechanisms, recognising the complexity and variability of chronic inflammatory disorders of the airways 5. All these efforts have been made to correlate the clinical phenotype to the course of the disease and its response to therapies 6. In 2013, the concept of endotyping in CRS first appeared 7. This consensus is the expression of the consciousness that CRS heterogeneity is supported by multiple biological subtypes (endotypes), each of which is defined by a distinct pathophysiological mechanism, determined equally by a well-defined genetic-environmental interaction. Each endotype should be in a theoretical line identified by a biomarker, to be intended both as diagnostic marker and as prognostic and therapeutic indicator. To find a highly predictive biomarker, a long series of key requirements for reproducibility, accessibility and stability must be met. In truth, we are still facing with the lack of an ideal biomarker that identifies CRS endotypes, allows a precise estimation of the severity of inflammation and predicts possible therapeutic responses. Therefore, it is likely that only a combination of biomarkers will be adequate to characterise each specific CRS subtype 8.

It is intrinsic to the concept of a multifactorial disease, as CRS, the existence not only of multiple predisposing factors (risk factors), but also of other concomitant pathological conditions (pre and comorbidities) that contribute in shaping the phenotype. Differentiation of pre- and comorbid and risk factors is not easy, because of the variability in disease definitions, the lack of longitudinal studies that establish temporal relationship between exposure and disease onset and the difficulty of assessing the dose-effect size on disease severity.

Furthermore, the opportunity to attest the effectiveness of “standard” therapies is limited by the wide variability of treatment types, patient selection and outcome assessments.

A non-negligible number of prior studies, which reported high proportions of patients improving following medical and/or surgical treatments, were, however, retrospective analyses, which deduced subjective parameters or collected results though unverified surveys 9. There was no standard for categorising preoperative status, extent of disease or surgical outcomes, and many of these studies were unable to interpret the clinical relevance of a specific treatment or further delineate subgroups of patients who did or did not experience improvement. In addition, single institution studies have been criticised for the potential lack of generalisability to patients population, an issue at least partially addressed by incorporating a multi-institutional study design 10 11. In the last years, the introduction of validated disease-specific quality of life (QoL) and general health-related QoL outcomes instruments allowed building a standard assessment of CRS patients.

Notwithstanding, in our opinion, the exclusive evaluation of outcomes based on symptomatic and objective scores (endoscopic, radiological) may be limitative. A previous prospective-designed publication showed that other clinical factors (such as asthma, ASA intolerance, prior sinus surgery etc.) were found to be important predictors of outcomes 10. Our idea is that patients affected by CRS should be framed as a whole, going beyond a sole rhinological point of view in a multidisciplinary perspective 12.

Consequently, a very frequent disease associated with multiple variables generates a large amount of data that should be collected. It clearly emerges that there is a need to establish a systematic approach for data collection and evaluation of outcomes.

Our tertiary care institution is working toward this direction and has created a CRS online database, called RhinoBank. Its advantages are many. First of all, it allows storing data in a single solution with the possibility of easily retrieving previously stored data. In addition, it provides the physician all the information at a glance, allowing location of missing data in a very simple way. Lastly, it enables data sharing with other work centres.

The aim of this letter is to present the efforts of our work in search of active collaboration. We are aware that the database can be further upgraded thanks to suggestions or implementations from other experts in the field. The database now contains only basic clinical information that can be routinely obtained in any hospital. It is not envisaged to store third level parameters such as genetic or biomolecular markers. This will be the next step, dictated by the possibility to perform a more detailed analysis in our institute.

The proposal is to spread this data collection system to other national centres to obtain large and uniform cohorts of patients. The goal is to overcome that lack of constant parameters, that is a critical element inside systematic reviews that hinders the possibility to draw conclusions on clinical practice 9. The database is at disposal for consultation at: https://www.rhinobank.eu/demo/admLoginWin.asp. (Account access: Username, Admin; Password, demo000.)